EP4774281A2 - Analogues de coiffe et leurs méthodes d'utilisation - Google Patents

Analogues de coiffe et leurs méthodes d'utilisation

Info

Publication number
EP4774281A2
EP4774281A2 EP24776717.1A EP24776717A EP4774281A2 EP 4774281 A2 EP4774281 A2 EP 4774281A2 EP 24776717 A EP24776717 A EP 24776717A EP 4774281 A2 EP4774281 A2 EP 4774281A2
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
nhc
och
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24776717.1A
Other languages
German (de)
English (en)
Inventor
Chunping Xu
Chanfeng Zhao
Alexandre V. Lebedev
Ilya Vladimirovich ILICHEV
Hengyuan Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trilink Biotechnologies LLC
Original Assignee
Trilink Biotechnologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trilink Biotechnologies LLC filed Critical Trilink Biotechnologies LLC
Publication of EP4774281A2 publication Critical patent/EP4774281A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention décrit de nouveaux analogues de coiffe de trétranucléotide et de trinucléotide, leurs procédés de production et leurs méthodes d'utilisation. L'invention concerne également des molécules d'ARN présentant une coiffe en 5', la coiffe en 5' comprenant un analogue de coiffe de tétranucléotide ou de trinucléotide tel que décrit ici. L'invention décrit en outre des méthodes d'induction d'un effet thérapeutique chez un sujet, les méthodes comprenant une étape d'administration au sujet d'une molécule d'ARN comprenant l'analogue de coiffe de trinucléotide.
EP24776717.1A 2023-09-06 2024-09-06 Analogues de coiffe et leurs méthodes d'utilisation Pending EP4774281A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363536844P 2023-09-06 2023-09-06
PCT/US2024/045502 WO2025054401A2 (fr) 2023-09-06 2024-09-06 Analogues de coiffe et leurs méthodes d'utilisation

Publications (1)

Publication Number Publication Date
EP4774281A2 true EP4774281A2 (fr) 2026-07-15

Family

ID=92895771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24776717.1A Pending EP4774281A2 (fr) 2023-09-06 2024-09-06 Analogues de coiffe et leurs méthodes d'utilisation

Country Status (7)

Country Link
EP (1) EP4774281A2 (fr)
KR (1) KR20260065838A (fr)
CN (1) CN121794279A (fr)
AU (1) AU2024337685A1 (fr)
IL (1) IL326531A (fr)
TW (1) TW202526022A (fr)
WO (1) WO2025054401A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026010855A1 (fr) 2024-07-02 2026-01-08 Trilink Biotechnologies, Llc Arn modifié pour augmenter l'expression de protéines
US20260185136A1 (en) * 2024-12-27 2026-07-02 Eisai R&D Management Co., Ltd. 5'-cap modifications of rna

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163251A1 (fr) 1999-03-24 2001-12-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES N-acylphosphoramidites et leur utilisation dans la synthese d'oligonucleotides
JP5558811B2 (ja) 2006-06-01 2014-07-23 トリリンク バイオテクノロジーズ 核酸増幅のための化学的に修飾されたオリゴヌクレオチドプライマー
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
PL248416B1 (pl) * 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
CN116368226A (zh) * 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
KR20220140140A (ko) * 2021-04-09 2022-10-18 한미정밀화학주식회사 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도
US20240327444A1 (en) * 2021-07-05 2024-10-03 Japan Science And Technology Agency Method for Purifying Nucleotides, Device for Purifying Nucleotides, Hy-Drophobic Reagent, and Hydrophobic Substrate
US20250122546A1 (en) * 2021-10-28 2025-04-17 BioNTech SE Rna constructs and uses thereof
WO2023167880A2 (fr) * 2022-03-01 2023-09-07 Verve Therapeutics, Inc. Compositions et méthodes de coiffage d'arn

Also Published As

Publication number Publication date
TW202526022A (zh) 2025-07-01
WO2025054401A2 (fr) 2025-03-13
WO2025054401A3 (fr) 2025-05-08
IL326531A (en) 2026-04-01
AU2024337685A1 (en) 2026-02-26
KR20260065838A (ko) 2026-05-11
CN121794279A (zh) 2026-04-03

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260218

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR